Aprea Therapeutics, Inc. (APRE)
NASDAQ: APRE · IEX Real-Time Price · USD
5.17
-0.15 (-2.82%)
At close: Apr 24, 2024, 3:15 PM
5.50
+0.33 (6.38%)
After-hours: Apr 24, 2024, 4:14 PM EDT
Company Description
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing synthetic lethality-based cancer therapeutics that targets DNA damage response pathways.
Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors, ovarian, breast, and prostate cancers.
The company is also developing ATRN-1051, ATRN-354, and APRE-DDRi for the treatment of advanced solid tumors.
The company is headquartered in Doylestown, Pennsylvania.
Aprea Therapeutics, Inc.
| Country | United States |
| Founded | 2006 |
| IPO Date | Oct 3, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 7 |
| CEO | Dr. Oren Gilad Ph.D. |
Contact Details
Address: 3805 Old Easton Road Doylestown, Pennsylvania 18902 United States | |
| Phone | 617-463-9385 |
| Website | atrinpharma.com |
Stock Details
| Ticker Symbol | APRE |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $15.00 |
| CIK Code | 0001781983 |
| CUSIP Number | 03836J102 |
| ISIN Number | US03836J2015 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Oren Gilad Ph.D. | Co-Founder, Chief Executive Officer, President and Director |
| John P. Hamill CPA | Senior Vice President, Chief Financial Officer, Principal Accounting Officer and Secretary |
| Dr. Dansu Li Ph.D. | Head of Technology |
| Dr. Lars B. Abrahmsen Ph.D. | Senior Vice President and Chief Scientific Officer |
| Dr. Michel Afargan Ph.D. | Head of Pharmacology Development |
| Ze'ev Weiss B.Sc., C.P.A. | Chief Business Advisor |
| Andrea Epstein | Controller |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 10, 2024 | 8-K | Current Report |
| Apr 3, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| Mar 26, 2024 | 8-K | Current Report |
| Mar 26, 2024 | 10-K | Annual Report |
| Mar 12, 2024 | 8-K | Current Report |
| Feb 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Feb 9, 2024 | 424B3 | Prospectus |
| Feb 7, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 6, 2024 | 8-K | Current Report |
| Feb 5, 2024 | 424B3 | Prospectus |